About Us

Bringing Vision to Life, Together

Vivacitas was formed in 2015, with the vision of our founders and Dr. Joseph Rubinfeld (co-founder of Amgen). Vivacitas is committed to creating new treatment options and improving the lives of cancer patients with solid tumors worldwide.

Cancer is the second leading cause of death in the United States. The global market for cancer therapeutics is growing rapidly, with revenues projected to reach $161 billion in 2026. (source: Allied Market Research 2021).

Currently, the standard of care for solid tumor cancers in the U.S is surgery and radiation/chemotherapy. Patients face significant challenges as treatment regimens must factor in the patient’s ability to tolerate the commonly used chemotoxins.

Significant numbers of cancer patients seek new treatment options especially in recurrent disease. According to the American Cancer Society, this is especially true in glioblastoma, colorectal, pancreatic, ovarian, and small cell lung cancers.

Team

We are founders, scientists, oncologists, biopharmaceutical experts, executives – and passionate people devoted to getting things done – hailing from start-up and multinational companies.

Driven by a shared mission, our team applies clarity, tenacity, and vision in our fight against cancer and the pursuit of new treatment options for patients and their families.

Executive Team

Mark Suseck

CEO &
Director

Scott VanderMeer, MBA

Interim CFO,
Director & Co-Founder

Tina Runk, MBA

EVP - Clinical Operations, Director
& Co-Founder

Elise Brownell, PhD

EVP - Portfolio Management

Peter Seperack, PhD, JD

Executive Director - Intellectual Property

Board of Directors

Chan Heng Fai

Chairman Emeritus
Alset International

Mark Suseck

CEO &
Director

Scott VanderMeer, MBA

Interim CFO,
Director & Co-Founder

Tina Runk, MBA

EVP -
Clinical Operations
Director
& Co-Founder

Jeff Stephens

Managing Director,
Infusion 51a
Director &
Co-Founder

Mamta Swaroop, MD

General Director, Infusion 51a
Founder, Sadanah Foundation
Director, Sadanah Trauma & Surgical Initiative

Frank Heuszel, JD

CEO Document Security Systems, Inc;
CEO American Pacific Bancorp

Medical & Scientific Advisors

Jai Grewal MD

NSPC Spine & Brain Surgery
Long Island, NY
Clinical Neuro-Oncologist
Executive Board Member American
Cancer Society

Andrew Lassman MD

Columbia University Irving Medical Center New York, NY John Harris Associate Professor of Neurology and Chief Neuro-Oncology, Columbia University Irving Medical Center

Katy Peters MD, PhD

Department of Neurology
Duke University School of Medicine Durham, NC
Associate Professor of Neurosurgery Director of Supportive Care

David Reardon MD

Dana-Farber Cancer
Institute: Harvard
School Boston, MA
Clinical Director,
Center for Neruo-Oncology

Volker Stieber MD

Novant Health Cancer Institute
Forsyth Medical Center
Winston-Salem, NC
Chair, IRB and Co-Chair, Neuro-Oncology Council

Gerard Blobe MD, PhD

Duke University School of Medicine
Durham, NC
Professor of Medicine
Associate Director,
Duke Cancer Institute

Erkut Borazanci MD, MS

HonorHealth Research Institute, University of Arizona College of Medicine
Scottsdale, AZ
Medical Oncology/Clinical Investigator
Clinical Assistant Professor, Internal Medicine

Lorem ipsum dolor
sit amet Vivamus id

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Eget rhoncus viverra tristique aliq uam et praesent adipiscing turpis auris.

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org